Alpha Cognition Inc.
ACOGNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · A1 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY15 | |
|---|---|---|---|---|
| Revenue | $10.2M | — | — | $100.0M |
| Operating income | −$22.7M | −$12.0M | −$9.9M | — |
| Net income | −$20.7M | −$14.8M | −$13.8M | — |
| Total assets | $79.7M | $50.7M | $2.5M | — |
| Total liabilities | $17.2M | $11.6M | $7.2M | — |
| Equity | $62.5M | $39.1M | −$4.7M | — |
| EPS (diluted) | $-1.18 | $-2.04 | $-3.84 | — |
| Shares out. | 16.0M | 16.0M | 4.7M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −221.7%
- Net margin
- −202.2%
- Return on equity
- −33.1%
- Return on assets
- −25.9%
- Return on capital (ROCE)
- −32.1%
- Liabilities / assets
- 21.6%
- Debt / equity
- 0.28×
- Book value / share
- $3.90
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.69safe
- Accruals / assets
- −0.4%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- ZUNVEYLJul 26, 2024
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Opaleye Management Inc.Passive (13G)May 22, 2026
- Manchester Management Co LlcPassive (13G)May 12, 2026
- Funicular Funds, LpPassive (13G)Feb 19, 2026
- Ikarian Capital, LlcPassive (13G)Feb 17, 2026
- Awm Investment Company, Inc.Passive (13G)Feb 13, 2026
- Solas Capital Management, LlcPassive (13G)Feb 14, 2025
- Besser James EPassive (13G)Jan 31, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Opaleye Management Inc.10% owner | May 27, 2026 | Buy | 1,161 | $5.73 |
| Opaleye Management Inc.10% owner | May 20, 2026 | Buy | 8,431 | $5.89 |
| D'Angelo LaurenOfficer — Chief Operating Officer | May 19, 2026 | Buy | 3,500 | $5.76 |
| Opaleye Management Inc.10% owner | May 15, 2026 | Buy | 16,648 | $5.83 |
| Sensenig BethanyDirector | Apr 16, 2026 | Grant | 5,489 | $0.00 |
| Opaleye Management Inc.10% owner | Mar 27, 2026 | Buy | 10,000 | $5.08 |
| Opaleye Management Inc.10% owner | Mar 24, 2026 | Buy | 4,182 | $5.59 |
| Opaleye Management Inc.10% owner | Mar 18, 2026 | Buy | 2,481 | $5.75 |
| Opaleye Management Inc.10% owner | Mar 16, 2026 | Buy | 1,331 | $5.78 |
| Opaleye Management Inc.10% owner | Mar 12, 2026 | Buy | 5,708 | $5.85 |
| Opaleye Management Inc.10% owner | Mar 6, 2026 | Buy | 1,900 | $5.80 |
| Opaleye Management Inc.10% owner | Mar 4, 2026 | Buy | 19,795 | $5.81 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 188,758 | 5.7 | +5.1% |
| Apr 30, 2026 | 179,560 | 3.8 | -12.6% |
| Apr 15, 2026 | 205,331 | 2.8 | -37.3% |
| Mar 31, 2026 | 327,498 | 5.5 | -1.9% |
| Mar 13, 2026 | 333,967 | 6.4 | +5.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeApr 20, 2026
- Entered a material agreementApr 14, 2026
- Regulation FD disclosureMar 27, 2026
- Results of operationsMar 26, 2026
- Director / officer changeFeb 23, 2026
- Director / officer changeJan 15, 2026
- Changed auditorOct 14, 2025
- Entered a material agreement · Other material eventOct 2, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 29, 2026
- 4May 22, 2026
- SCHEDULE 13G/AMay 22, 2026
- 4FORM 4May 19, 2026
- 4May 19, 2026
- 10-QQUARTERLY REPORTMay 14, 2026
- SCHEDULE 13G/AMay 12, 2026
- SCHEDULE 13G/AMay 11, 2026
- 8-K/AFORM 8-K/AMay 1, 2026
- DEFA14ADEFINITIVE ADDITIONAL MATERIALSApr 30, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 30, 2026
- 8-KFORM 8-KApr 20, 2026
- 4FORM 4Apr 17, 2026
- 3FORM 3Apr 17, 2026
- 8-KCURRENT REPORTApr 14, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.